This drug may cause photosensitivity reactions, avoid exposure to direct sunlight and UV light.
Monitor lymecycline serum levels.
Decreased absorption w/ Ca, Al, Mg, bismuth and zinc salts, antacids, bismuth containing ulcer-healing drugs, Fe preparations and quinapril. Increased effects of anticoagulants. Decreased plasma levels w/ barbiturates, phenytoin or carbamazepine. Potentially Fatal: Increased risk of kidney failure w/ methoxyflurane. Increased risk of benign intracranial HTN w/ oral retinoids.
May cause false-positive urine glucose determinations. May also interfere w/ fluorometric determinations of urine catecholamines resulting in falsely increased values (Hingerty's method).
Description: Lymecycline is a tetracycline derivative which blocks the access of bacterial aminoacyl-tRNA to the mRNA-ribosome complex by binding to the 30S ribosome subunit, preventing the addition of amino acids to the growing peptide chain in protein synthesis. Pharmacokinetics: Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: W/in 3-4 hr. Distribution: Distributed in most body tissues and fluids, and notably in the lungs, bones, muscles, liver, bladder, prostate, bile and urine. Crosses the placenta and enters breast milk. Excretion: Mainly via urine and secondarily in the bile. Plasma half-life: Approx 10 hr.
J01AA04 - lymecycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections.
Buckingham R (ed). Lymecycline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/03/2016.Joint Formulary Committee. Lymecycline. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/03/2016.